Results 221 to 230 of about 172,015 (263)
Some of the next articles are maybe not open access.
Use of CMV transcripts for monitoring of CMV infections in transplant recipients
International Journal of Antimicrobial Agents, 2000The development of the nucleic acid sequence-based amplification (NASBA) technology has allowed qualitative determination of human cytomegalovirus (HCMV) immediate-early (IE) and late (pp67) transcripts for monitoring of HCMV infections in the post transplantation period.
Gerna, G +3 more
openaire +4 more sources
Optometry and Vision Science, 1995
ABSTRACT The two drugs known to be useful in the treatment of cytomegalovirus (CMV) retinitis are ganciclovir and foscarnet—usually they are given intravenously. Intravitreal ganciclovir seems to be even more effective. A pump system to deliver the drug into the vitreous is being developed.
openaire +2 more sources
ABSTRACT The two drugs known to be useful in the treatment of cytomegalovirus (CMV) retinitis are ganciclovir and foscarnet—usually they are given intravenously. Intravitreal ganciclovir seems to be even more effective. A pump system to deliver the drug into the vitreous is being developed.
openaire +2 more sources
Reviews in Medical Virology, 2002
AbstractAmong the human herpesviruses, cytomegalovirus (CMV) is the only one that has assumed significant importance in blood transfusion. Transfusion transmission of CMV (TT‐CMV) to seronegative immunocompromised patients can lead to lethal CMV disease.
openaire +2 more sources
AbstractAmong the human herpesviruses, cytomegalovirus (CMV) is the only one that has assumed significant importance in blood transfusion. Transfusion transmission of CMV (TT‐CMV) to seronegative immunocompromised patients can lead to lethal CMV disease.
openaire +2 more sources
Human CMV vaccine trials: What if CMV caused a rash?
Journal of Clinical Virology, 2008There are no apparent biologic obstacles to immunization against fetal/placental infection with cytomegalovirus (CMV), and vaccine candidates have been developed. The major obstacles for a human CMV vaccine are difficulties associated with the design and execution of efficacy trials.
openaire +2 more sources